Australia Inhalation Anesthesia Market Size & Outlook
Australia inhalation anesthesia market, 2018-2030 (US$M)
Related Markets
Australia inhalation anesthesia market highlights
- The Australia inhalation anesthesia market generated a revenue of USD 20.5 million in 2022 and is expected to reach USD 43.5 million by 2030.
- The Australia market is expected to grow at a CAGR of 9.8% from 2023 to 2030.
- In terms of segment, sevoflurane was the largest revenue generating drug in 2022.
- Isoflurane is the most lucrative drug segment registering the fastest growth during the forecast period.
Inhalation anesthesia market data book summary
| Market revenue in 2022 | USD 20.5 million |
| Market revenue in 2030 | USD 43.5 million |
| Growth rate | 9.8% (CAGR from 2022 to 2030) |
| Largest segment | Sevoflurane |
| Fastest growing segment | Isoflurane |
| Historical data | 2016 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sevoflurane, Desflurane, Isoflurane |
| Key market players worldwide | Baxter International Inc, AbbVie Inc, Fresenius SE & Co KGaA, Sandoz Group AG ADR, Piramal Enterprises, Halocarbon Products Corporation, Lunan Pharmaceutical Group |
Other key industry trends
- In terms of revenue, Australia accounted for 1.7% of the global inhalation anesthesia market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China inhalation anesthesia market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 104.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Inhalation Anesthesia Market Scope
Inhalation Anesthesia Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia inhalation anesthesia market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inhalation anesthesia market will help companies and investors design strategic landscapes.
Sevoflurane was the largest segment with a revenue share of 63.41% in 2024. Horizon Databook has segmented the Australia inhalation anesthesia market based on sevoflurane, desflurane, isoflurane covering the revenue growth of each sub-segment from 2018 to 2030.
Australia's market is driven by the number of surgeries continues to rise due to both elective procedures and emergency cases. Collaborations between local distributors and multinational companies are common to ensure market penetration and timely product supply.
The Australian government’s healthcare spending is expected to play a critical role in the expansion of the inhalation anesthesia market, as investments in public health infrastructure increase access to surgeries and medical procedures.
Reasons to subscribe to Australia inhalation anesthesia market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia inhalation anesthesia market databook
-
Our clientele includes a mix of inhalation anesthesia market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia inhalation anesthesia market , including forecasts for subscribers. This country databook contains high-level insights into Australia inhalation anesthesia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia inhalation anesthesia market size, by drug, 2018-2030 (US$M)
Australia Inhalation Anesthesia Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
